No Data
No Data
J.P. Morgan Securities Co., Ltd.: The Cellectis (CLLS.US) rating was reaffirmed and adjusted from superior to superior market rating, and the target price was adjusted from $6.00 to $6.00.
J.P. Morgan Securities Co., Ltd.: The Cellectis (CLLS.US) rating was reaffirmed and adjusted from superior to superior market rating, and the target price was adjusted from $6.00 to $6.00.
JMP Securities Reiterates Market Outperform on Cellectis, Maintains $6 Price Target
JMP Securities analyst Silvan Tuerkcan reiterates Cellectis with a Market Outperform and maintains $6 price target.
Cellectis Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/31/2024 122.97% JMP Securities $6 → $6 Reiterates Market Outperform → Market Outperform 11/01/2023 122.
Positive Outlook for Cellectis SA With Strategic AstraZeneca Partnership and Promising Clinical Developments
Earnings Call Summary | Cellectis(CLLS.US) Q1 2024 Earnings Conference
The following is a summary of the Cellectis S.A. (CLLS) Q1 2024 Earnings Call Transcript:Financial Performance:Cellectis reported a net income of $5.6 million for Q1 2024, reflecting a significant imp
Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Cellectis SA (CLLS) and Sanofi (OtherSNYNF)
No Data